The mechanisms underlying the effects of psychostimulants in attention deficit hyperactivity disorder (ADHD) are not well understood, but indirect evidence implicates D2 dopamine receptors. Here we dissect the components of dopaminergic neurotransmission in the hyperactive mouse mutant coloboma to identify pre-and postsynaptic elements essential for the effects of amphetamine in these mice. Amphetamine treatment reduced locomotor activity in coloboma mice, but induced a robust increase in dopamine overflow suggesting that abnormal regulation of dopamine efflux does not account for the behavioral effect. However, the D2-like dopamine receptor antagonists haloperidol and raclopride, but not the D1-like dopamine receptor antagonist SCH23390, blocked the amphetamine-induced reduction in locomotor activity in coloboma mice, providing direct evidence that D2-like dopamine receptors mediate the effect of amphetamine in these mice. With the precedent established that it is possible to directly antagonize this response, this strategy should prove useful for identifying novel therapeutics in ADHD.
Introduction
Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsivity and hyperactivity. A familiar feature of ADHD is the response to psychostimulants such as methylphenidate (Ritalin) and D-amphetamine (Adderall) . Both compounds are indirect agonists that increase extracellular monoamine concentrations (Ferris et al., 1972; Heikkila et al., 1975) . In ADHD patients, low doses of stimulants produce beneficial behavioral effects by reducing excess motor activity and enhancing concentration. Although the efficacy of psychostimulants in ADHD was recognized nearly 70 years ago (Bradley, 1937) , the biological mechanisms are not understood.
Many theories, including several that focus on dopaminergic transmission, have emerged to explain the effects of psychostimulants. The rate dependency hypothesis suggests that the effect of psychostimulants in hyperactive children is a phenomenon driven by behavioral state (Glick and Milloy, 1973; Sahakian and Robbins, 1977) . The locomotor response to psychostimulants is an inverted U-shaped function: low doses increase locomotor activity and high doses induce focused behaviors (stereotypy) that compete with and consequently reduce locomotor activity. Drugnaive ADHD patients are at the highest point on this inverted Ushaped curve. Accordingly, the psychostimulant-induced reduction in motor activity is ascribed to an increase in stereotyped behavior. Others propose that low doses of stimulants reduce synaptic catecholamine concentrations or the amplitude of impulse-induced dopamine release (McCracken, 1991; Seeman and Madras, 1998; Solanto, 1998) . Low doses of direct-acting dopamine agonists preferentially interact with presynaptic receptors to inhibit dopamine release and therefore reduce locomotor activity (Skirboll et al., 1979) . By extension, it is proposed that low doses of the indirect agonists methylphenidate and amphetamine reduce locomotor activity in ADHD patients through a similar mechanism of action. Others suggest that psychostimulant therapy compensates for insufficient dopamine transmission in the frontal cortex while reducing nigrostriatal overactivity (Castellanos, 1997) . Despite these and other well-developed hypotheses, there is little empirical evidence to explain the therapeutic mechanism of psychostimulants in ADHD.
Animal models of ADHD provide an opportunity to explore pathogenic and therapeutic mechanisms. The coloboma mouse mutant is one such model. These mice exhibit hyperactivity, inattention and delayed developmental milestones (Hess et al., 1992; Heyser et al., 1995; Bruno et al., 2007) plus abnormal monoaminergic regulation (Raber et al., 1997; Jones and Hess, 2003) . These defects are attributable, at least in part, to a reduction in the expression of SNAP-25 (Hess et al., 1996) , a protein
